# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-s...
Truist Securities analyst Srikripa Devarakonda downgrades Incyte (NASDAQ:INCY) from Buy to Hold and lowers the price target ...
JMP Securities analyst Reni Benjamin reiterates Incyte (NASDAQ:INCY) with a Market Perform.
Guggenheim analyst Michael Schmidt maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $86 to $92.
Cantor Fitzgerald analyst Eric Schmidt reiterates Incyte (NASDAQ:INCY) with a Neutral.
B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $66 to...
Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secon...
New antitumor response data from a range of doses and regimens unveiled today at Incyte investor event These results build u...